Background: High-security hospital patients are often complex in presentation and are characterized by treatment resistance, medication nonadherence and history of violence. Paliperidone is licensed both as an oral and depot antipsychotic medication in the treatment of schizophrenia. Clinical trials have shown that paliperidone depot is well tolerated with similar efficacy to risperidone depot but with additional practical advantages. Whilst data exist for the effectiveness of paliperidone palmitate (PP), there are no studies involving patients in forensic settings or those with comorbid personality disorder. Our aim was to evaluate the effectiveness of PP on violence, aggression and personality disorder symptoms. Methods: This project was a retrospective service evaluation involving 11 patients, carried out in a high-security hospital. A combination of patient records and interviews with the treating consultant psychiatrist were used to ascertain a Clinical Global Impression (CGI) score, the effect of PP on specific personality disorder symptom domains (cognitive-perceptual, impulsive-behavioural dyscontrol and affective dysregulation) and incidents of violence and aggression. Engagement with occupational and psychological therapies was also evaluated. Metabolic parameters were reviewed. Results: A total of 6 out of 11 patients continued on PP, most of whom had schizophrenia and dissocial personality disorder with histories of violence. All showed improvement in the CGI score with associated benefits in the three personality symptom domains. Overall, two patients demonstrated a reduction in the risk of violence. There was improvement in engagement with occupational therapy and psychological work. No significant effects on metabolic parameters were noted although hyperprolactinaemia, albeit asymptomatic, was consistently recorded. Conclusions: This pragmatic service evaluation of a small but complex patient group demonstrated, for the first time, that PP was effective in reducing violence as well as improving personality pathology across all dimensions: a finding which could have significant implications for management of such high-security patients.
Introduction
Paliperidone (9-hydroxyrisperidone) is the major active metabolite of risperidone [Bishara, 2010] . It is effective in the treatment of schizophrenia [Pandina et al. 2011 ] and is licensed both as an oral and depot antipsychotic medication. In the largest [Pandina et al. 2010 ] of four short term, randomized double-blind studies evaluating effectiveness in the acute stages of illness, paliperidone palmitate (PP) was compared with placebo over 13 weeks. It was demonstrated that the mean change in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to endpoint improved significantly in all the PP dose groups (25, 100, 150 mg eq). These findings were supported by three smaller studies Kramer et al. 2009; Nasrallah et al. 2010 ].
Paliperidone has also been shown to delay relapse , significantly decrease hospitalizations [Kozma et al. 2011] and the average number of bed days per year [Taylor and Attard, 2013] . As well as being non-inferior to risperidone long-acting injectable (RIS-LAI) [Pandina et al. 2011] , PP is relatively well tolerated [Pandina et al. 2011 ]. It has additional practical advantages over RIS-LAI, namely faster onset of action negating the need for oral supplementation in the first weeks of treatment, fewer monthly injections, a smaller needle, and a saving in nursing time because of provision in a prefilled syringe.
High-security hospital patients often have complex presentations that are marked by comorbidity, violence, poor concordance with oral medication and treatment resistance [Gibbon et al. 2011] . Although RIS-LAI and olanzapine pamoate have been demonstrated as showing a clinical benefit in these patients [Gibbon et al. 2011; Baruch et al. 2014] , there is a scarcity of literature about the role of depot antipsychotic medication in this subgroup and there is no previously published work evaluating the effects of PP.
We report a service evaluation involving the use of PP depot in 11 patients within a high-security hospital in the UK. This project was retrospective in design involving review of the case records, and aimed at evaluating the clinical effectiveness of PP; specifically, its effect on personality disorder symptoms and violent behaviour.
Methods
All patients were inpatients at the high-security hospital Broadmoor, UK. There are three highsecurity hospitals in England and Wales, caring for a population of 56 million. High-security hospitals treat patients who have committed serious offences, have severe psychiatric conditions and therefore pose the highest level of risk to others, such that they cannot be managed in other levels of secure hospital environments.
Typically, in Broadmoor Hospital, the commonest diagnosis is schizophrenia followed by personality disorder. Patients are detained under the Mental Health Act and include patients transferred from less secure hospital units, prisons or those that receive a hospital treatment order at sentencing from court. The hospital has wards that are distinguished by the level of dependency or risk that the patient poses. This ranges from intensive care or high dependency to rehabilitation wards from where patients are discharged. Patients are discharged primarily to less secure hospitals or repatriated to prison once their treatment is complete.
All patients were diagnosed by the treating consultant psychiatrist as having paranoid schizophrenia and a dissocial personality disorder aside from two, who had diagnoses of schizoaffective disorder (Table 1) . All were admitted with histories of serious violence along with psychotic symptoms. All clinical diagnoses were made using the criteria of the International Statistical Classification of Diseases and Related Health Problems, 10th revision [World Health Organization, 1992] . None of the patients had a history of learning disability, brain injury or epilepsy. Overall, one patient had a diagnosis of polysubstance dependence syndrome (currently in remission). Patients had an average age of 35.3 years.
Patients were included in the evaluation if they had been on PP for a period of 2 months. They were identified using the hospital pharmacy database. Doses of PP for each patient were recorded and any changes in these doses and any concurrent medications were noted.
In total, 17 patients in the hospital were or had been prescribed PP. It was not possible to approach two patients as the treating consultant deemed the patient not to have the capacity to consent to participate in the project and one patient had not been on PP for the required amount of time (2 months). Therefore, the remaining 14 patients were approached individually for informed consent and 11 patients consented to participate and provided written informed consent. This project was approved as a service evaluation not requiring ethic committee approval by the hospital's Audit committee.
The primary outcome measure was CGI [Guy, 1976] ; specifically, severity of illness (CGI-S). CGI is a commonly used scale for measuring the effect of pharmacological intervention in various studies on personality disorders [Frankenburg and Zanarini, 1993; Binks et al. 2006 ]. CGI scores were ascertained before starting PP and during treatment with PP in the most recent 6 months.
The CGI-S score prior to starting PP was ascertained through review of data collected from the patients' clinical notes. The clinical notes included Care Programme Approach documentation, Mental Health Act Review Tribunal reports, Historical, Clinical, Risk Management-20 forms [Webster et al. 1995] and the hospitals' physical health centre records. Data were anonymized.
CGI-S scores post-starting PP (i.e. over the most recent 6 months) were ascertained through interview with the treating consultant psychiatrist. Outcome variables [Soloff, 1997; Ingenhoven et al. 2010] were also derived through interview with the treating consultant psychiatrist according to the following personality symptom domains: cognitive-perceptual, impulsive-behavioural dyscontrol and affective dysregulation. The psychiatrists were asked to rate the patients' degree of improvement in the most recent 6 months as having 'worsened', 'remained the same', had 'some improvement' or 'much improvement'. For those patients that had discontinued PP the psychiatrists were asked to rate degree of improvement at the time of stopping PP. For one patient whose consultant had left the hospital assessment pre-and post-PP was conducted by the principal author.
The cognitive-perceptual domain included symptoms of paranoia, suspiciousness and quasi psychotic symptoms; the impulsive-behavioural dyscontrol domain included impulsive behaviour, self-harm, agitation and aggression to person and property and the affective dysregulation domain contained emotional responses of low mood, anxiety, anger and mood lability.
Secondary outcome measures were incidents and episodes of violence and aggression and engagement with the multidisciplinary team, specifically occupational therapy and psychological therapy.
To gain a clinical impression of the patients' risk of violence the hospital electronic incident recording system in combination with clinical records was reviewed. A patients' risk of violence was assessed using a combination of the logged incidents as well as episodes of aggression documented in clinical notes which did not necessarily meet the hospital incident reporting system standards. This was ascertained for a 6-month period prior to starting PP and for the most recent 6 months.
The hospital's incident reporting system is an electronic intranet system where staff members log every clinical incident for each patient. It has been used for a number of years to generate information about incident trends in the hospital and is reliable and comprehensive. Reports for each patient were generated and these were used to determine the number of incidents which had occurred in the 6 months prior to the start of PP and in the most recent 6 months.
The measure of aggression was subdivided into verbal aggression, aggression against property, aggression against the person and self-harm. In addition, there was a group that encompassed behaviour which did not fit in to the other categories which we termed threatening behaviour. Planned moves to wards of lower or higher dependency within the hospital were noted. Engagement with occupational therapy, vocational activities and psychological therapies were also recorded in the 6 months preceding commencing PP and in the most recent 6 months.
In addition, information about patients' body mass index (BMI), cholesterol, glucose and prolactin levels before and after starting PP was collected. This was from the hospital physical health centre records.
Demographic data and information used to determine treatment resistance according to the International Psychopharmacology Algorithm Project (IPAP) criteria [IPAP, 2006] were obtained from clinical records.
Results
Of the 11 patients, PP had been discontinued in 6, however 1 of these patients had stopped but restarted PP and was included in the report. Therefore, six patients continued to receive PP; four patients were prescribed a dose of 150 mg every 4 weeks and two patients 75 mg every 4 weeks.
A number of patients were taking concurrent psychotropic medication. All medications had been started prior to PP except for mirtazapine (patient D) which had been started after initiation of PP. All patients had dose changes of their concurrent medication during treatment with PP.
Symptom improvement
All six patients who continued PP (patients A-F) showed improvement by a reduction in the CGI-S score of at least 1 point (Table 2) . Overall, one of these patients demonstrated a reduction by 2 points and one patient by 4 points.
Of the personality symptom domains, five of the six patients showed improvement in the cognitive-perceptual domain; three of these showed 'much improvement'. A total of five of the six patients showed improvement in the impulsivebehavioural dyscontrol domain; two of these showed 'much improvement'. All patients showed improvement in some aspect of affective dysregulation; three patients showed improved symptoms of low mood, three in anxiety, four demonstrated improved anger control and five showed an improvement in mood stability.
Of those that had discontinued PP (patients G-K) there was no improvement in CGI scores. However, there had been improvements reported in aspects of personality for some of these patients.
Improvement in aggression and violence
Of the patients that continued PP (patients A-F), two patients that demonstrated episodes of violence in the 6 months prior to starting PP showed a reduction in the number of episodes recorded compared with the most recent 6 months (Table 3) .
Overall, two patients that had no incidents remained the same and two patients showed an increase in violence ( Figure 1) ; patient C had an increase in verbal aggression and threatening behaviour (one incident in the 6 months pre-PP versus two incidents in the most recent 6 months) and patient E had an increase in aggression against the person (no incidents pre-PP versus one incident in the most recent 6 months) and threatening behaviour (no incidents pre-PP versus one incident in the most recent 6 months). There were no incidents of self-harm.
During the period of treatment with PP, three patients had progressed from a higher dependency ward and two of the six patients were being prepared for a move to a lower level of security (medium security).
Of those that discontinued PP (patients G-K), three patients showed an increase in risk. The subcategories which showed the most frequent increase were aggression against property and aggression against the person. 
Engagement with the multidisciplinary team
In all cases where PP was continued there was improved engagement with the multidisciplinary team (Table 3) . Improved engagement was also seen in patient I during treatment with PP as well as a move to a lower dependency ward. This patient had stopped PP due to pain at the injection site.
Metabolic parameters and side effects
There was no significant effect on fasting blood glucose or cholesterol levels, however, hyperprolactinaemia (albeit asymptomatic) was consistently recorded. There was a small decrease in fasting blood sugar results in four patients. There was a small decrease in total cholesterol: HDL (high density lipid) ratio in two patients. Prolactin levels increased in three patients by an average of 756 mU/l. BMI increased in three patients and decreased in four patients over the duration of PP treatment. The mean average increase in BMI was <1 point (0.49). Findings were limited due to absence of some data.
All patients reported a similar profile of side effects; most frequently were dry mouth, extrapyramidal side effects and blurred vision. A total of one patient reported excessive tiredness.
Patients that discontinued PP
Of the six patients that discontinued PP, the most common reasons for stopping were lack of efficacy (three patients) and pain at the injection site (two patients).
Patient F who restarted PP had stopped due to lack of efficacy. Between the two periods of PP prescription, patient F had been prescribed olanzapine depot and commenced on sodium valproate. Olanzapine was stopped and PP restarted whilst sodium valproate was continued. There was clinical improvement. It was noted that aripiprazole was prescribed for 4 weeks during the second treatment period of PP.
Of the patients that discontinued PP subsequent medications switched to were zuclopenthixol (patient G), haloperidol depot (patient H), oral aripiprazole later changed to depot (patient I), oral aripiprazole for 2 months followed by zuclopenthixol (patient J) and oral risperidone (patient K).
Discussion
We report a service evaluation of 11 patients, mostly with diagnoses of paranoid schizophrenia or schizoaffective disorder and dissocial personality disorder with histories of significant interpersonal violence who were treated with PP in the setting of a high-security hospital. All six patients showed clinical improvement during treatment with PP. Maximum improvement seen in the personality domains was in the severity of affective dysregulation symptoms, specifically lability of mood and anger control. Overall, two patients had reduction in violent incidents, in two there were no such incidents before or after starting PP, and in two there was an increase in incidents. All patients showed an improvement in engagement with the multidisciplinary team to varying degrees. Metabolic parameters were largely unchanged although prolactin levels increased.
For the purpose of this report we examined all patients who were prescribed PP in the hospital and after excluding patients who did not have capacity or did not consent, 11 patients were included in the report and outcomes for these patients are described. It is notable that all but one of the 11 patients were treatment-resistant. Additionally, five patients discontinued PP and three did so for lack of efficacy and two for pain at the injection site. Therefore, approximately half of the patients we report continued on PP, and all those who continued showed clinical benefits. It is notable that for one patient, improvement in clinical efficacy was seen following a combination of PP and a mood stabilizer.
In terms of clinical outcomes, we focussed on those that would be relevant for a forensic psychiatric patient such as reduction in incidents of aggression and reduction in risk. As all patients also had a diagnosis of dissocial personality disorder, we examined clinical response in domains of personality characteristics, which are additionally relevant to clinical improvement in a forensic hospital setting.
For those that continued PP, the medication was relatively well tolerated.
Pharmacodynamic rationale for treatment with paliperidone
Paliperidone is a dopamine D 2 and serotonin 5-HT 2A receptor antagonist. Like other atypical antipsychotics it has a high 5-HT 2A :D 2 affinity ratio. It also acts as an antagonist at α 1 and α 2 adrenergic and H 1 histaminergic receptors .
Animal studies suggest that dopamine has considerable influence in mediating emotion, stress response, aggression and impulsivity [Harrison et al. 1997; Vukhac et al. 2001; Wade et al. 2000] .
Additionally, several studies have demonstrated the association between abnormal dopamine metabolite (HVA) levels and impulsivity [Chotai et al. 1998 ]. These effects are particularly relevant to borderline and dissocial personality disorders which are characterized by emotional dysregulation and impulsivity [Friedel, 2004] . Dopamine dysfunction has been postulated as an underlying pathology in borderline personality disorder and this is supported by evidence that personality disorder symptoms can be treated by neuromodulators which improve dopamine dysfunction [Adams, 1979] .
It has also been shown that serotonin (5HT) has a key role in the modulation of aggressive behaviour [Friedel, 2004; Adams, 1979; Berman et al. 1997; Brown, 1982; De Boer and Koolhaas, 2005; Gowin et al. 2010; Miczek et al. 2002; Moss et al. 1990] , and several studies have identified an association between the serotonin metabolite (5-HIAA) in human cerebrospinal fluid and antisocial behaviour such as violence, homicide, arson and child abuse. The extent to which serotoninergic dysfunction influences aggression is dependent on a complex interplay between multiple environmental factors [Moss et al. 1990] .
Through its complex action on both the dopaminergic and serotonergic system, it can be postulated that paliperidone induces anti-aggressive properties which can be of benefit in the treatment of personality disorders.
Existing literature
It is difficult to compare our results with current literature due to the scarcity of studies reporting on pharmacological treatment in this subgroup of patients.
We have considered the role of concurrent medication in view of two patients taking mood stabilizers, two patients taking an additional antipsychotic, one patient taking two antidepressants and one patient taking regular diazepam. All can contribute to improvement in symptom domains.
A meta-analysis [Ingenhoven et al. 2010] examined the actions of psychotropic medication on various symptom domains in severe personality disorder. It found that antipsychotics rather than mood stabilizers or antidepressants led to improvement in cognitive-perceptual symptoms, whereas, improvements in impulsive-behavioural dyscontrol and in affective dysregulation were found to respond to either antipsychotics, antidepressants or mood stabilizers. Therefore, the mechanism for improvement in the cognitive-perceptual domain may be due to improvement in potential dopamine dysfunction, whereas, impulsive behaviour dyscontrol and affective dysregulation domains are governed in addition by potential serotonin and noradrenergic dysfunction [Umukoro et al. 2012 ].
Our findings demonstrate improved functioning in all symptom domains, which may be attributed to the diverse spectrum of receptor actions by paliperidone, especially on dopaminergic and serotonergic systems.
Our patients were detained in a high-security hospital by virtue of posing the highest level of risk of violence towards others. It is important to note that there was a reduction in this risk as demonstrated by a reduction in incidents, movement to lower dependency wards and preparation for transfer to a lower level of security. Whilst this may be due to an anti-aggressive property of paliperidone, it may be secondary to improvement in cognitive-perceptual or impulsive-behavioural dyscontrol domains.
Important considerations
The retrospective nature of this case-series, small sample and lack of objective rating scales with regard to some aspects of data collection such as engagement with therapies are limitations that need to be appreciated before drawing any firm conclusions from our findings.
Studies conducted in a high-security hospital typically involve patients who are considered extreme not only in terms of their presentation and associated risks, but also in their management, which limits the ability of our results to be generalized. This evaluation had no control other than the individuals own prior records pre-starting PP. It also did not control for confounding variables such as other medications, psychological therapies and the therapeutic relationship between patient and the treating team.
However, this is a naturalistic service evaluation and has the advantage of allowing the authors to evaluate large volumes of data in a longitudinal perspective for all patients. This was afforded by all participants being inpatients in a setting with stringent and detailed recording of clinical information. Additionally, in such a setting, there are no confounding factors in the form of concurrent substance misuse or irregular/lack of adherence to medications. All patients reported in this case-series were fully concordant with PP treatment.
Cost−benefit and future recommendations All the patients had been transferred to highsecurity hospital services from medium-security hospitals or from custodial settings due to unmanageable aggression and subsequent need for treatment. High-security hospital care is expensive in comparison with these alternatives and therefore, if proved beneficial, PP would be of an immense cost−benefit to the health service. Effective treatment with PP in these patients would reduce the duration of high-security hospital stay and encourage progression to a medium-security hospital or return to prison services, thereby mitigating the overall cost of treatment.
However, there is a considerable lack of evidence to support treatment with PP in the forensic setting. Additionally, research exploring pharmacotherapy in forensic patients is difficult to conduct and the subjects that are enrolled in randomized control trials are not representative of the most difficult-to-manage patients in secure units [Volavka and Citrome, 1999; Brown et al. 2014] . A previous study using a similar study design from our setting showed promising results for the depot olanzapine pamoate [Baruch et al. 2014 ], but further research in this area is warranted.
Conclusion
PP is an atypical antipsychotic which has been shown to improve symptoms in schizophrenia. We report our experience of PP treatment not only in patients with schizophrenia but also schizoaffective disorder and comorbid dissocial personality disorder, in the setting of a high-security hospital. We found that all patients who continued PP achieved clinical benefit. To the best of our knowledge, this is the first time that PP has been shown to be of benefit in reducing violence and aggression as well as improving personality pathology dimensions in patients with a comorbidity of dissocial personality disorder. A depot antipsychotic effective in reducing violence in addition to improving psychotic symptoms is a significant addition to the armamentarium of forensic psychiatrists for the future management of high-security forensic patients.
We are modest in our conclusions, however, and interpretations should be taken in the context of the nature of the evaluation and the limitations associated with it. Given the low number of patients, this service evaluation should be considered as exploratory. Further studies are required over a longer period of time to build up a robust pool of data on the efficacy of this medication and its role in reducing violent behaviour in patients with psychosis; especially schizophrenia.
